Table 5 Guideline characteristics within GI tool categories
Guideline characteristic (n GI tools) | GI tool category (n, %) | |||
|---|---|---|---|---|
Patient | Clinician | Implementation | Evaluation | |
Overall (464) | 113 (24.4) | 239 (51.5) | 66 (14.2) | 46 (9.9) |
Condition | ||||
 Diabetes | 37 (32.7) | 64 (26.8) | 20 (30.3) | 9 (19.6) |
 Stroke | 26 (23.0) | 63 (26.4) | 8 (12.1) | 3 (6.5) |
 Heart failure | 15 (13.3) | 48 (20.1) | 14 (21.2) | 11 (23.9) |
 Asthma | 15 (13.3) | 30 (12.6) | 4 (6.1) | 1 (2.2) |
 Arthritis | 12 (10.6) | 13 (5.4) | 6 (9.1) | 4 (8.7) |
 Depression | 5 (4.4) | 20 (8.4) | 10 (15.2) | 7 (15.2) |
 Colorectal cancer | 3 (2.7) | 1 (0.4) | 4 (6.1) | 11 (23.9) |
Country | ||||
 United States | 62 (54.9) | 121 (50.6) | 16 (24.2) | 0 (0.0) |
 United Kingdom | 28 (24.8) | 38 (15.9) | 41 (62.1) | 44 (95.7) |
 Canada | 21 (18.6) | 60 (25.1) | 8 (12.1) | 1 (2.2) |
 Australia | 1 (0.9) | 9 (3.8) | 0 (0.0) | 1 (2.2) |
 International group | 1 (0.9) | 7 (2.9) | 0 (0.0) | 0 (0.0) |
 Singapore | 0 (0.0) | 2 (0.8) | 1 (1.5) | 0 (0.0) |
 Brazil | 0 (0.0) | 2 (0.8) | 0 (0.0) | 0 (0.0) |
 Finland | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
 Spain | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
Organization | ||||
 Government agency | 39 (34.5) | 48 (20.1) | 40 (60.6) | 39 (84.8) |
 Professional society | 23 (20.4) | 97 (40.6) | 13 (19.7) | 2 (4.3) |
 Disease foundation | 18 (15.9) | 37 (15.5) | 4 (6.1) | 4 (8.7) |
 Academic institution | 29 (25.7) | 31 (13.0) | 6 (9.1) | 0 (0.0) |
 Non-profit agency | 4 (3.5) | 25 (10.5) | 3 (4.5) | 1 (2.2) |
 International group | 0 (0.0) | 1 (0.4) | 0 (0.0) | 0 (0.0) |